50461-37-5

Basic information

• Product Name: 5-methoxy-2-methyl-3-(methylsulfanyl)-1H-indole
• CAS NO: 50461-37-5
• Molecular Formula: C₁₁H₁₃NOS
• Molecular Weight: 207.292
• Mol File: 50461-37-5.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 365°C at 760 mmHg
• Flash Point: 174.6°C
• Density: 1.2g/cm³
• Vapor Pressure: 3.39E-05mmHg at 25°C
• Refractive Index: 1.636
• CAS DataBase Reference: 5-methoxy-2-methyl-3-(methylsulfanyl)-1H-indole(CAS DataBase Reference)
• NIST Chemistry Reference: 5-methoxy-2-methyl-3-(methylsulfanyl)-1H-indole(50461-37-5)
• EPA Substance Registry System: 5-methoxy-2-methyl-3-(methylsulfanyl)-1H-indole(50461-37-5)

Safety Data

• Hazardous Substances Data: 50461-37-5(Hazardous Substances Data)

Upstream product

• 624-92-0 Dimethyldisulphide 
• 1076-74-0 5-methoxy-2-methyl-1H-indole 

Downstream Products

• 1076-74-0 5-methoxy-2-methyl-1H-indole 

Relevant articles and documents

Synthesis and biological properties of aryl methyl sulfones

A novel group of aryl methyl sulfones based on nonsteroidal anti-inflammatory compounds exhibiting a methyl sulfone instead of the acetic or propionic acid group was designed, synthesized and evaluated in vitro for inhibition against the human cyclooxygenase of COX-1 and COX-2 isoenzymes and in vivo for anti-inflammatory activity using the carrageenan induced rat paw edema model in rats. Also, in vitro chemosensitivity and in vivo analgesic and intestinal side effects were determined for defining the therapeutic and safety profile. Molecular modeling assisted the design of compounds and the interpretation of the experimental results. Biological assay results showed that methyl sulfone compounds 2 and 7 were the most potent COX inhibitors of this series and best than the corresponding carboxylic acids (methyl sulfone 2: IC50 COX-1 = 0.04 and COX-2 = 0.10 μM, and naproxen: IC50 COX-1 = 11.3 and COX-2 = 3.36 μM). Interestingly, the inhibitory activity of compound 2 represents a significant improvement compared to that of the parent carboxylic compound, naproxen. Further support to the results were gained by the docking studies which suggested the ability of compound 2 and 7 to bind into COX enzyme with low binding free energies. The improvement of the activity of some sulfones compared to the carboxylic analogues would be performed through a change of the binding mode or mechanism compared to the standard binding mode displayed by ibuprofen, as disclosed by molecular modeling studies. So, this study paves the way for further attention in investigating the participation of these new compounds in the pain inhibitory mechanisms. The most promising compounds 2 and 7 possess a therapeutical profile that enables their chemical scaffolds to be utilized for development of new NSAIDs.